These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
243 related articles for article (PubMed ID: 14676055)
1. Levetiracetam for phasic spasticity in multiple sclerosis. Hawker K; Frohman E; Racke M Arch Neurol; 2003 Dec; 60(12):1772-4. PubMed ID: 14676055 [TBL] [Abstract][Full Text] [Related]
2. Open-label pilot trial of levetiracetam for cramps and spasticity in patients with motor neuron disease. Bedlack RS; Pastula DM; Hawes J; Heydt D Amyotroph Lateral Scler; 2009 Aug; 10(4):210-5. PubMed ID: 18821142 [TBL] [Abstract][Full Text] [Related]
3. The effect of levetiracetam on tremor severity and functionality in patients with multiple sclerosis. Feys P; D'hooghe MB; Nagels G; Helsen WF Mult Scler; 2009 Mar; 15(3):371-8. PubMed ID: 19168602 [TBL] [Abstract][Full Text] [Related]
4. Levetiracetam in clinical practice: long-term experience in patients with refractory epilepsy referred to a tertiary epilepsy center. Bootsma HP; Ricker L; Diepman L; Gehring J; Hulsman J; Lambrechts D; Leenen L; Majoie M; Schellekens A; de Krom M; Aldenkamp AP Epilepsy Behav; 2007 Mar; 10(2):296-303. PubMed ID: 17317325 [TBL] [Abstract][Full Text] [Related]
5. Meta-analysis of the efficacy and safety of Sativex (nabiximols), on spasticity in people with multiple sclerosis. Wade DT; Collin C; Stott C; Duncombe P Mult Scler; 2010 Jun; 16(6):707-14. PubMed ID: 20558502 [TBL] [Abstract][Full Text] [Related]
6. Single-dose bioavailability of levetiracetam intravenous infusion relative to oral tablets and multiple-dose pharmacokinetics and tolerability of levetiracetam intravenous infusion compared with placebo in healthy subjects. Ramael S; De Smedt F; Toublanc N; Otoul C; Boulanger P; Riethuisen JM; Stockis A Clin Ther; 2006 May; 28(5):734-44. PubMed ID: 16861095 [TBL] [Abstract][Full Text] [Related]
7. A randomized trial of memantine as treatment for spasticity in multiple sclerosis. Mehta LR; McDermott MP; Goodman AD; Schwid SR Mult Scler; 2010 Feb; 16(2):248-51. PubMed ID: 20028712 [TBL] [Abstract][Full Text] [Related]
8. Tizanidine treatment of spasticity caused by multiple sclerosis: results of a double-blind, placebo-controlled trial. US Tizanidine Study Group. Smith C; Birnbaum G; Carter JL; Greenstein J; Lublin FD Neurology; 1994 Nov; 44(11 Suppl 9):S34-42; discussion S42-3. PubMed ID: 7970009 [TBL] [Abstract][Full Text] [Related]
9. Neurocognitive effects of adjunctive levetiracetam in children with partial-onset seizures: a randomized, double-blind, placebo-controlled, noninferiority trial. Levisohn PM; Mintz M; Hunter SJ; Yang H; Jones J; Epilepsia; 2009 Nov; 50(11):2377-89. PubMed ID: 19702752 [TBL] [Abstract][Full Text] [Related]
10. [Botulinum toxin treatment of hip adductor spasticity in multiple sclerosis]. Wissel J; Entner T Wien Klin Wochenschr; 2001; 113 Suppl 4():20-4. PubMed ID: 15506048 [TBL] [Abstract][Full Text] [Related]
11. Functional outcome of intrathecal baclofen administration for severe spasticity. Boviatsis EJ; Kouyialis AT; Korfias S; Sakas DE Clin Neurol Neurosurg; 2005 Jun; 107(4):289-95. PubMed ID: 15885386 [TBL] [Abstract][Full Text] [Related]
12. Add-on levetiracetam in children and adolescents with refractory epilepsy: results of an open-label multi-centre study. Callenbach PM; Arts WF; ten Houten R; Augustijn P; Gunning WB; Peeters EA; Weber AM; Stroink H; Geerts Y; Geerts AT; Brouwer OF Eur J Paediatr Neurol; 2008 Jul; 12(4):321-7. PubMed ID: 17950011 [TBL] [Abstract][Full Text] [Related]
13. A clinical study of intrathecal baclofen using a programmable pump for intractable spasticity. Guillaume D; Van Havenbergh A; Vloeberghs M; Vidal J; Roeste G Arch Phys Med Rehabil; 2005 Nov; 86(11):2165-71. PubMed ID: 16271565 [TBL] [Abstract][Full Text] [Related]
14. Levetiracetam as an adjunctive analgesic in neoplastic plexopathies: case series and commentary. Dunteman ED J Pain Palliat Care Pharmacother; 2005; 19(1):35-43. PubMed ID: 15814513 [TBL] [Abstract][Full Text] [Related]
15. Correlation of increase in phosphene threshold with reduction of migraine frequency: observation of levetiracetam-treated subjects. Young W; Shaw J; Bloom M; Gebeline-Myers C Headache; 2008; 48(10):1490-8. PubMed ID: 19076647 [TBL] [Abstract][Full Text] [Related]
16. Effect of levetiracetam on cardiac repolarization in healthy subjects: a single-dose, randomized, placebo- and active-controlled, four-way crossover study. Hulhoven R; Rosillon D; Bridson WE; Meeus MA; Salas E; Stockis A Clin Ther; 2008 Feb; 30(2):260-70. PubMed ID: 18343264 [TBL] [Abstract][Full Text] [Related]
17. A pilot study of a comparison between a patient scored numeric rating scale and clinician scored measures of spasticity in multiple sclerosis. Anwar K; Barnes MP NeuroRehabilitation; 2009; 24(4):333-40. PubMed ID: 19597271 [TBL] [Abstract][Full Text] [Related]
18. Levetiracetam monotherapy in children with epilepsy. Khurana DS; Kothare SV; Valencia I; Melvin JJ; Legido A Pediatr Neurol; 2007 Apr; 36(4):227-30. PubMed ID: 17437904 [TBL] [Abstract][Full Text] [Related]
19. Clinical development of levetiracetam for amyotrophic lateral sclerosis. Davies SL; Moral MA Drug News Perspect; 2006 Nov; 19(9):572-3. PubMed ID: 17220961 [TBL] [Abstract][Full Text] [Related]
20. Adjunctive levetiracetam in infants and young children with refractory partial-onset seizures. PiƱa-Garza JE; Nordli DR; Rating D; Yang H; Schiemann-Delgado J; Duncan B; Epilepsia; 2009 May; 50(5):1141-9. PubMed ID: 19243423 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]